<DOC>
	<DOCNO>NCT00603447</DOCNO>
	<brief_summary>To evaluate safety maximum tolerate dose ( MTD ) carfilzomib combination lenalidomide dexamethasone patient relapse multiple myeloma</brief_summary>
	<brief_title>Phase 1b Multicenter Study Carfilzomib With Lenalidomide Dexamethasone Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Disease relate : 1 . Symptomatic multiple myeloma 2 . Relapsed progressive disease least one three prior therapeutic treatment regimens multiple myeloma 3 . Prior therapeutic treatment regimen may include bortezomib , lenalidomide , and/or thalidomide , among agent . 4 . If previously treat lenalidomide bortezomib , subject must progress first 3 month treatment drug must discontinue treatment due lenalidomide intolerance ( bortezomib intolerant subject may enroll ) . 5 . Measurable disease , indicate one following : Serum Mprotein ≥ 0.5 g/dL Urine BenceJones protein ≥ 200 mg/24 h If Serum Protein Electrophoresis felt unreliable routine Mprotein measurement ( particularly patient Immunoglobulin ( Ig ) A multiple myeloma ) , quantitative immunoglobulin level accept . 6 . Prior enrollment , sit must provide evidence myeloma progression/relapse , start stop date recent treatment regimen , well best tumor response prior treatment regimen . Demographic 7 . Males females ≥ 18 year age 8 . Life expectancy three month 9 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Laboratory 10 . Adequate hepatic function , bilirubin &lt; 2 time upper limit normal ( ULN ) alanine aminotransferase ( ALT ) &lt; 3 time ULN 11 . Absolute neutrophil count ( ANC ) ≥ 1,000/mm³ , hemoglobin ≥ 8 gm/dL , platelet count ≥ 50,000/ mm³ ( ≥ 30 × 10^9/L myeloma involvement bone marrow &gt; 50 % ) Screening ANC independent granulocyte granulocyte/macrophage colony stimulate factor ( GCSF GMCSF ) support least 1 week pegylated GCSF least 2 week . Subjects may receive red blood cell ( RBC ) platelet transfusion , clinically indicate , accordance institutional guideline Screening platelet count independent platelet transfusion least 2 week 12 . Calculated measured creatinine clearance ≥ 50 mL/minute , calculate use formula Cockcroft Gault [ ( 140 Age ) x Mass ( kg ) / ( 72 x creatinine mg/dL ) ] ; multiply result 0.85 ( female ) . Other generally accept calculation method substitute . Ethical/Other 13 . Written inform consent accordance federal , local , institutional guideline 14 . Females childbearing potential ( FCBP ) must agree ongoing pregnancy test 15 . FCBP* must negative serum urine pregnancy test , sensitivity least 50 mIU/mL within 1014 day ( US/RevAssist® ) 25 mIU/mL within 714 day ( Canada/RevAidSM ) , prior within 24 hour start lenalidomide must either commit continued abstinence heterosexual intercourse use two method reliable birth control , include least one highly effective method AND one additional effective method birth control ( contraception ) AT THE SAME TIME , begin 4 week prior initiate treatment lenalidomide , therapy , therapy delay , continue 4 week follow discontinuation lenalidomide therapy . If hormonal method ( birth control pill , injection , patch implant ) intrauterine device ( IUD ) medically possible subject , subject may use another highly effective method two barrier method AT THE SAME TIME . 16 . Male subject must agree NEVER unprotected sexual contact female become pregnant must agree either completely abstain sexual contact female pregnant able become pregnant , must use latex condom EVERY TIME engage sexual contact female pregnant may become pregnant take lenalidomide 4 week stops take drug , even successful vasectomy . The subject must agree inform physician unprotected sexual contact female become pregnant think FOR ANY REASON , sexual partner may pregnant . 17 . Male subject donate semen sperm take lenalidomide . 18 . All study participant must register mandatory RevAssist ( US ) RevAid ( Canada ) program willing able comply requirement Rev Assist/RevAid 19 . Subjects must adhere study visit schedule protocol requirement receive outpatient treatment laboratory monitor institute administers drug 20 . Subjects must agree take entericcoated aspirin 81325 mg orally daily , history prior thrombotic disease allergy aspirin , must fully anticoagulated warfarin ( INR 23 ) treat fulldose , low molecular weight heparin , treat deep venous thrombosis ( DVT ) /pulmonary embolism . Disease relate 1 . Subjects nonsecretory hyposecretory multiple myeloma , define &lt; 0.5 g/dL Mprotein serum , &lt; 200 mg/24 hr Bence Jones protein urine , disease measure serum free light chain ( FLC ) 2 . Subjects never achieve least durable minimal response ( MR , ≥ 25 % reduction Mprotein least 6 week ) prior therapy 3 . Corticosteroid therapy dose equivalent dexamethasone ≥ 4 mg/day prednisone ≥ 20 mg/day within 3 week prior first dose 4 . Use experimental drug therapy within 28 day baseline 5 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 6 . Plasma cell leukemia 7 . Waldenström 's macroglobulinemia 8 . Chemotherapy approve investigative anticancer therapeutic , include steroid therapy dose define , within 3 week prior first dose 9 . Radiation therapy immunotherapy within 4 week prior first dose ; localize radiation therapy within 1 week prior first dose 10 . Planned radiation therapy occur start treatment 11 . Participation investigational therapeutic study within 3 week within 5 drug halflives ( t1/2 ) prior first dose , whichever time great . Concurrent condition 12 . Pregnant lactating female 13 . History allergy boron mannitol 14 . Major surgery within 3 week prior first dose 15 . Congestive heart failure ( New York Heart Association class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention myocardial infarction previous six month 16 . Uncontrolled hypertension 17 . Acute active infection require systemic antibiotic , antiviral , antifungal within two week prior first dose 18 . Known suspected human immunodeficiency virus ( HIV ) infection , know HIV seropositivity , active hepatitis A , B , C infection 19 . Nonhematologic malignancy within past three year except 1. adequately treat basal cell squamous cell skin cancer , 2. carcinoma situ cervix , 3. prostate cancer &lt; Gleason Grade 6 stable prostate specific antigen ( PSA ) level 20 . Serious psychiatric medical condition could interfere treatment 21 . Significant neuropathy ( Grade 3 , Grade 4 , Grade 2 pain ) time first dose and/or within 14 day enrollment 22 . Contraindication require concomitant drug , include protonpump inhibitor ( e.g. , lansoprazole ) , entericcoated aspirin anticoagulant , history prior thrombotic disease , warfarin low molecular weight heparin 23 . Subjects require program oral intravenous fluid hydration contraindicate , e.g. , due preexist pulmonary , cardiac , renal impairment 24 . Subjects know suspected amyloidosis 25 . Subjects pleural effusion require thoracentesis ascites require paracentesis 26 . Prior carfilzomib treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>